

### Strong growth provides the platform for the next commercial phase

*Biovica ended the fiscal year with strong growth in both the fourth quarter and for the full fiscal year, while making important progress in expanding the clinical evidence base, the Pharma Services area, and adoption of DiviTum TKa in the USA. Biovica is embarking on the next commercial phase with a sharper focus, higher efficiency, and greater financial discipline.*

**Q4 (Feb 2026 – April 2026)** (comparison figures are for the same period 2024/2025)

- Net sales amounted to SEK 4,815 (2,332), corresponding to an increase of 107%. In local currency, net sales increased by 129%.
- Cash flow from operating activities amounted to SEK -15,984 (- 17,826) thousand.
- At the end of the quarter, cash and cash equivalents amounted to SEK 70,412 (24,415) thousand.

**Fiscal year 25/26 (May 2025– April 2026)**

(comparison figures are for the same period 24/25)

- Net sales amounted to SEK 13,380 (8,619), corresponding to an increase of 55%. In local currency, net sales increased by 74%.
- Cash flow from operating activities during the period amounted to SEK -62,807 (- 85,367) thousand.

#### Significant events during the fourth quarter

- Data confirm strong prognostic correlations for DiviTum TKa in metastatic breast cancer.
- Biovica's CEO, Anders Rylander, announced that he will step down as CEO during 2026 as part of a structured succession process.
- New AACR data expand evidence for TKa in immunotherapy-treated patients and CDK inhibitor dose optimization.
- The Board of Directors has appointed Theis Kipling as the new CEO, effective 1 May 2026.

#### Significant events after the end of the quarter

- New ESMO data highlights TKa across multiple treatment settings.
- CFO Anders Morén has resigned on his own initiative. He will remain in his current role during the six-month notice period.
- Biovica received an expanded work order from a clinical-stage oncology company developing a next-generation CDK inhibitor.
- New Phase III data shows that DiviTum TKa captures treatment-specific biological response for metastatic breast cancer.
- Biovica initiates termination of Distribution contracts within EU to focus resources on US and Pharma Services

SEK 000s	Q4	25/26	Q4	24/25	May-April	May-April
					25/26	24/25
Net sales		4,815		2,332	13,380	8,619
Operating profit (loss)		-18,043		-20,341	-70,119	-85,839
Profit (loss) for the period		-19,122		-20,766	-69,860	-87,624
Earnings per share, after dilution (note 3)		-0.07		-0.21	-0.30	-0.95
Number of shares at the end of the period	291,911,199		97,786,384		291,911,199	97,786,384
Cash and cash equivalents at the end of the period		70,412		24,415	70,412	24,415
Cash flow from operating activities		-15,984		-17,826	-62,807	-85,367
Average number of employees		25		26	24	26

Webcast: <https://www.redeye.se/events/1170839/live-q-biovica>

When: 17 June 2026, 3 PM to 4 PM CET, Broadcast in English

#### Biovica in brief – Treatment decisions with greater certainty

- Biovica develops and commercializes the blood-based biomarker assay, DiviTum® TKa, which enables early-stage evaluation of treatment effectiveness. The initial focus is on breast cancer.
- DiviTum TKa has obtained FDA 510(k) clearance in the USA and has CE marking in the EU.
- Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B).

## CEO's comments

During the fourth quarter of fiscal year 2025/26, Biovica further strengthened its position in the IVD market and Pharma Services in the U.S. I assumed the role of CEO on 1 May 2026, just as the company enters the next important phase of its commercial growth. After my first month as CEO, my assessment of the company is clear: Biovica has a strong scientific foundation, a differentiated product and considerable potential.

My mandate is thus to make Biovica more focused, more efficient and more commercially impactful. Through a sharper allocation of resources toward the most value-creating opportunities, we can improve cash flow, enhance resilience, and accelerate progress toward our strategic ambitions.

Our path forward is clear. We will continue to expand the body of clinical evidence, accelerate commercial adoption, and deepen our collaboration with leading clinics, healthcare providers, payers, and pharmaceutical companies. At the same time, we must sharpen our priorities and allocate resources to the areas with the greatest value-creation potential, creating a more efficient organization with improved cash flow. These important initiatives will strengthen Biovica's financial resilience and create better conditions for realizing the commercial potential.

### **Growing body of evidence**

Further progress was made during the quarter in expanding the body of clinical evidence. New data presented during the period confirmed the strong prognostic correlations for DiviTum TKa in metastatic breast cancer, reinforcing the test's clinical utility as a decision-support tool in treatment selection. Additionally, new data presented at the American Association for Cancer Research (AACR) Annual Meeting expanded the clinical evidence supporting the use TKa in immune checkpoint inhibitor therapy and CDK inhibitor dose optimization.

Subsequent to the end of the fiscal year, new data was presented at ESMO Breast Cancer 2026 highlighting the utility of TKa across a variety of treatment settings, reinforcing its relevance as a dynamic biomarker for treatment monitoring and drug development. It aligns well with the growing demand for biomarkers that support more personalized oncology treatment.

### **Sharper commercial focus**

Demand in Pharma Services remains strong, driven by the need for validated pharmacodynamic (PD) biomarkers in clinical development and heightened regulatory focus on dose optimization. Our collaborations with leading pharmaceutical companies continue to advance through recurring and expanded assignments, underscoring the importance of this business area as a key growth driver for Biovica.

We are also seeing growing commercial momentum in the U.S., where adoption of DiviTum TKa continues to increase steadily. This confirms that prior investments in establishing a market presence are now translating into concrete clinical use. Going forward, we will continue to build on this foundation through a more disciplined commercial model, clearer customer prioritization, and better alignment across clinical evidence generation, payer engagement, and go-to-market activities.

### **More focused strategy and improved cash flow**

My first priority going forward is to ensure that Biovica is properly structured for the next phase of growth, with the right organization, cost base, and commercial focus. We must therefore prioritize the markets, customer segments, and partnerships that offer the greatest potential for product adoption, revenue growth, and long-term strategic value. The objective is not merely to reduce costs, but to create a more focused, efficient and sustainable organization. By improving financial discipline, sharpening priorities, and allocating resources more effectively, we can

better capitalize on the investments already made in clinical evidence, regulatory acceptance, and commercial infrastructure.

**Well positioned for the next phase**

We enter the new fiscal year with strong momentum and a clear set of priorities: to accelerate adoption of DiviTum TKa, broaden its use, deepen our strategic partnerships, and ensure that Biovica operates more efficiently and with greater financial discipline. The growing body of evidence, our established presence in the USA, and a stronger position in Pharma Services provide a solid foundation for the next phase of the company’s growth.

I would like to sincerely thank Biovica’s employees for their commitment and work during this important period for the company. The talent, expertise, and drive within the organization are important assets as we move into this next phase.

My priority as CEO is clear – to realize Biovica’s commercial potential through streamlining initiatives and a more scalable business model. Doing so will better position the company to achieve its strategic ambitions and deliver long-term value to patients, healthcare providers, and shareholders.



Theis Kipling, CEO

## Significant events during the fourth quarter

### ***Data confirm strong prognostic correlations for DiviTum TKa in metastatic breast cancer***

Results from the prospective PDM-MBC (Personalised Disease Monitoring in Metastatic Breast Cancer) study were published in Breast Cancer Research and Treatment. The results show that DiviTum TKa provides robust prognostic information on both progression-free and overall survival across several early time points. The findings also indicate that thymidine kinase 1 activity (TKa) acts as a continuous risk marker with potential to support more personalized follow-up strategies.

### ***Anders Rylander announced his intention to step down as CEO during 2026 as part of a structured succession process.***

In the meantime, Anders Rylander will remain in the role to ensure continuity and an orderly handover.

### ***New AACR data expands evidence for TKa in immunotherapy-treated patients and CDK inhibitor dose optimization.***

The studies expand the evidence for circulating thymidine kinase activity (TKa), measured with Biovica's DiviTum TKa assay, as a pharmacodynamic biomarker in oncology drug development. New data in immunotherapy-treated (ICI) lung cancer patients strengthen TKa's role in immuno-oncology research, while results from the CDK inhibitor study further supports the biomarker's utility in preclinical models, clinical studies, and routine clinical monitoring.

### **The Board of Directors for Biovica has appointed Theis Kipling as the new CEO. He assumed the position on 1 May 2026.**

He has extensive international experience in leading global commercial operations across the life science and diagnostics sectors. He has a strong track record of driving global sales growth and building high-performing commercial organizations. Most recently, he served as Chief Commercial Officer at Devyser Diagnostics and previously as Chief Commercial Officer at Atlas Antibodies.

## Summary of significant events during first three quarters

### ***Biovica signed an agreement with Tempus AI in the USA***

Biovica signed an agreement with Tempus AI, which is a leader in AI and data-driven precision medicine. The aim is to expand the commercial reach of DiviTum TKa.

### ***Biovica signed a new Master Service Agreement (MSA) with a US-based pharma/biotech company.***

An initial work order valued at approximately SEK 4 million was also signed.

### ***New data on DiviTum TKa use in three areas of cancer presented at ASCO***

Biovica presented three abstracts based on studies with DiviTum TKa at ASCO. The new data further reinforces DiviTum TKa's role as a predictive biomarker across three different cancer indications:

- Hormone receptor-positive (HR+) metastatic breast cancer (MBC) in patients treated with CDK4/6 inhibitors, as studied in the high-profile PEARL trial
- BRAF V600-mutated metastatic melanoma treated with immune checkpoint inhibitors (ICIs)
- Ovarian cancer treated with platinum-based chemotherapy

### ***Biovica secured three new assignments worth SEK 2.5 million in the Pharma Services part of the business***

Two of the three work orders were placed by the US-based Tier 1 pharmaceutical company (with revenues exceeding USD 10 billion) that recently entered into a broader service agreement with Biovica. These latest orders will support development of next generation CDK4/6 inhibitors. The assignments include a combination of retrospective analyses, to be conducted over the coming months, and prospective analyses, scheduled to take place over an estimated two-year period.

### ***Biovica signed an agreement with its fifth Tier 1 biopharma company in the USA.***

Biovica signed a new Master Service Agreement (MSA) and received an initial work order of approximately SEK 800 thousand. It is the fifth Tier 1 biopharma company in the USA to join the Biovica customer base in Pharma Services.

### ***Biovica has been granted a new European patent***

The patent covers the use of TKa as a marker for predicting the efficacy of immune checkpoint

inhibitor (ICI) treatment in cancer patients. The patent will enter into force on 16 July 2025 in connection with its publication in European Patent Bulletin.

***Biovica received work order for SEK 3 million – the fourth from this Tier 1 pharma company.***

It is the fourth work order, worth SEK 3 million, from this leading Tier 1 pharmaceutical company. The project is expected to be fully executed during fall 2025.

***Biovica launched DiviTum TKa for use in early breast cancer***

It will be available as a laboratory developed test (LDT) from Biovica's CLIA-certified laboratory in the USA. The launch opens up a new market that could result in a potential fivefold expansion of the addressable market for DiviTum TKa.

***New issues generated SEK 122.3 million prior to issue costs***

A rights issue generated approximately SEK 80.1 million prior to issue costs and a directed share issue to the investors who entered into guarantee undertakings as top-down guarantors (the "Anchor Investors") generated additional liquidity of approximately SEK 42.2 million prior to issue costs. The set-off of a bridge loan generated approximately SEK 10.1 million. In total, the company received approximately SEK 122.3 million prior to issue costs.

***Two new studies with DiviTum TKa presented at SABCS 2025***

Both studies highlight the clinical relevance of DiviTum TKa as a dynamic biomarker for monitoring treatment response.

Researchers from Yale Cancer Center evaluated whether early TKa measurements could identify suboptimal CDK4/6 inhibitor activity caused by medication non-adherence or drug interactions. A multi-center case series by the Mass General Brigham Cancer Institute and Siteman Cancer Center at Washington University in St. Louis examined the associations between baseline circulating tumor DNA (ctDNA) profiles and early TKa response patterns. The case studies demonstrated how ctDNA and TKa provide complementary insights – ctDNA reveals resistance biology, while TKa reflects treatment response in real time.

***Biovica signed a commercial agreement with a leading US cancer center that will increase availability of DiviTum TKa***

The agreement strengthens Biovica's presence among leading US cancer institutions. It also

supports introduction at a leading academic cancer center and the company's commercialization in the USA.

***Data from the Ciclib trial at Roswell Park Comprehensive Cancer Center published in JCO Precision Oncology***

The study evaluated breast cancer patients enrolled in the prospective Ciclib trial at Roswell Park, assessing whether thymidine kinase could serve as a clinically useful and accessible biomarker. The results demonstrated that thymidine kinase activity levels measured with Biovica's DiviTum TKa test at baseline and during therapy reflected treatment sensitivity and the emergence of resistance. The publication adds to a growing base of evidence supporting DiviTum TKa as a valuable monitoring and predictive biomarker in both metastatic and early breast cancer settings.

Significant events after the end of the period

***New data presented at ESMO highlight the utility of TKa in multiple treatment settings***

Three posters including TKa measurements were presented at the ESMO Breast Cancer 2026 Annual Congress, held in Berlin during 6–8 May 2026. The presentations highlight how TKa can be used to monitor treatment response, disease progression and biological treatment effect across several clinically relevant settings for metastatic breast cancer.

***CFO Anders Morén has resigned on his own initiative***

He will remain in his current role during the six-month notice period to ensure a smooth transition. The company has initiated the recruitment process to appoint a successor and will inform the market when additional information is available.

***Biovica received an expanded work order from a clinical-stage oncology company developing a next-generation CDK inhibitor***

The expanded work order amounts to approximately USD 75,000 (SEK 700,000). The company has previously engaged Biovica in multiple projects related to its leading oncology program, and the current engagement represents the fourth work order between the parties, further strengthening the collaboration. The expanded collaboration was initiated following promising initial TKa biomarker findings generated within the ongoing Phase I program, which led to broader integration of longitudinal TKa testing to further evaluate biological drug activity and proliferation dynamics during treatment.

DiviTum TKa has also been used in the partner's IND-enabling development activities as part of the translational biomarker package supporting the program's progression into clinical development.

***New data published in European Journal of Cancer***

Data shows that DiviTum TKa can capture early, treatment-specific biological response in patients with endocrine-resistant HR+/HER2– metastatic breast cancer. The authors also highlight that TKa provides unique information that may complement ctDNA. While ctDNA provides important genomic information about tumor mutations and clonal evolution, TKa provides a functional, real-time readout of tumor proliferation and biological treatment activity. In simple terms, ctDNA can help show what genetic changes are present, while TKa can help show what the cancer is doing during treatment.

***Biovica initiates negotiations regarding the termination of distribution agreements within the EU***

Biovica has initiated negotiations on the termination of the European distribution agreements in order to focus its operations on the IVD market in the U.S. and the global Pharma Services business.

**Other**

***2026 AGM***

Biovica's Annual General Meeting will be held on 16 September 2026 in Uppsala. Notice of the AGM will be published on Biovica's website, in Post- och Inrikes Tidningar (gazette) and in SvD (newspaper). The Board of Directors proposes that no dividends should be distributed to shareholders.

# Comments on the financial performance of the Group

## Q4 - Sales and earnings

Sales in the fourth quarter are generated from two main areas: Pharma Services and Testing Services. Within Pharma Services, Biovica primarily targets pharmaceutical companies, offering Tests (RUO) and Kits (RUO). Within Testing Services, Biovica offers Tests (IVD) for clinical diagnostics in the US market through its CLIA laboratory in San Diego.

Net sales for the period amounted to SEK 4,815 (2,332) thousand, corresponding to an increase of 106% compared to the same period previous year (+129% in local currency). The main growth driver is Pharma Services, where sales increased significantly by more than 160%.

In the Pharma Services area, sales of Tests (RUO) increased by approximately SEK 2.5 million, corresponding to more than 750%. Sales of Kits (RUO) decreased slightly compared to the same period prior year. It corresponds to the trend of more major pharmaceutical companies choosing to send samples to Biovica for analysis, rather than purchasing the kit and doing the analysis themselves.

The sale of Tests (IVD) – USA also grew, with an increase of SEK 165 thousand, corresponding to an increase of 18% (+35% in local currency) compared to the same period prior year. Please see Note 1 for more information.

The operating loss for the period was SEK -18,043 (-20,341) thousand.

Net financial items amounted to SEK 346 (100) thousand. Loss after financial items was SEK -17,697 (-20,240) thousand. Loss for the period was SEK -19,122 (-20,766) thousand.

The average number of employees for the quarter was 25 (26) employees, of which 13 (15) are women.

## Full year 2025/2026 - Sales and earnings

Sales in the year are derived from two main areas: Pharma Services and Testing Services. Within Pharma Services, Biovica primarily targets pharmaceutical companies, offering Tests (RUO) and Kits (RUO). Within Testing Services, Biovica offers Tests (IVD) for clinical diagnostics in the US market through its CLIA laboratory in San Diego.

Net sales for the year amounted to SEK 13,380 (8,619) thousand, corresponding to an increase of 55 percent (+74% in local currency).

Sales for Pharma Services were SEK 9,231 thousand, corresponding to an increase of 72% on an annual basis (+91% in local currency). In the Pharma Services area, the largest increase came from Tests (RUO), which increased by 204 percent (+248% in local currency). Sales of Kits (RUO) to pharmaceutical companies decrease by 24 percent (-18% in local currency) compared to the previous year. This reflects the trend of an increasing number of major pharmaceutical companies using Biovica's Testing Services and purchasing Tests (RUO), rather than purchasing Kits (RUO) and performing the analysis themselves. It also reflects the closer collaboration between Biovica and its pharmaceutical customers. In our other main area, Testing Services, the sale of Tests (IVD) – USA were SEK 4,086 (2,953) thousand, corresponding to an increase of 38% on an annual basis (+55% in local currency). More information is provided in Note 1

The operating loss for the year was SEK -70,119 (-85,839) thousand.

Net financial items amounted to SEK 611 (-143) thousand. Loss after financial items was SEK -69,508 (-85,982) thousand. Loss for the period was SEK -69,860 (-87,624) thousand.

The average number of employees for the year was 24 (26) employees, of which 14 (14) are women.

## Financial position, funding and investments

The closing amount for cash & cash equivalents on 30 April 2026 was SEK 70,412 (24,415) thousand.

During the period, a rights issue and directed issue to anchor investors of the rights issue were carried out in order to generate the capital required for the continued launch of DiviTum TKa. The proceeds from this were approximately SEK 122.3 million prior to issue costs and the set-off of a bridge loan.

The Board of Directors has performed a comprehensive assessment of the company's financing needs and liquidity position. The assessment is based on the company's cash and cash equivalents of approximately SEK 70 million at the end of the period, as well as a forecast approved by the Board of Directors regarding sales development and cost structure. Based on this analysis, the Board of Directors assesses that the company has sufficient resources to continue its operations for the foreseeable future which means minimum next 12 months after this report has been published.

The Board of Directors' assessment is based on assumptions regarding future sales development and costs. If actual outcomes differ materially from the assumptions underlying the forecast, this could affect the company's liquidity and, consequently, its ability to continue as a going concern. Accordingly, the Board of Directors has not identified any material uncertainties that could raise significant doubt about the company's ability to continue as a going concern, based on currently known circumstances. Accordingly, the Board of Directors considers the use of the going concern basis of accounting to be appropriate in the preparation of the financial statements.

Net investments in property, plant and equipment in the form of equipment for the year amounted to SEK -474 (-287) thousand.

For details on impairment testing, please see the Annual Report 2024/2025. The WACC used for impairment testing during the year is 32.4% (31.9%).

## Related party transactions

During the fourth quarter, the company, represented by parties related to the main owner and board member, Anders Rylander, leased office facilities to the Parent Company. The total fee for rent paid during the quarter was SEK 75 (68) thousand. Transactions were in accordance with market-based terms and conditions.

During the 2025/2026 fiscal year, the company, represented by parties related to the main owner and board member, Anders Rylander, leased office facilities to the Parent Company. The total fee for rent paid during the financial year was SEK 278 (271) thousand. Transactions were in accordance with market-based terms and conditions.

During the fiscal year, companies represented by and related to Board member CP (Niels) Bogerd provided consulting services related to sales support and sales support systems. Total fees amounting to SEK 77 (0) thousand were paid. Transactions were in accordance with market-based terms and conditions.

## Financial comments, Parent Company

Sales for the Parent Company are lower compared to the previous year, which is primarily attributable to a new transfer pricing model introduced at the start of 2025. Financial comments for the Parent Company are otherwise, in all material respects, consistent with those for the Group.

## Incentive programs

Program	To	Country	Options / Saving Shares	Subscription price	Subscription period	Equity Increase	Number of class B shares	Dilution
23/26:1*	Employees	US	240,000	10.13	1 June–30 September 2026	16,000	240,000	0.08%
23/26:2*	Employees	US	56,000	10.12	11 July 2023–15 September 2026	3,733	56,000	0.02%
23/26:3*	Employees	SE	358,000	8.24	1 October- 1 November 2026	23,867	358,000	0.12%
23/26:4*	Board of Directors	SE	195,000	8.24	1 October- 1 November 2026	13,000	195,000	0.07%
23/26:5*	Employees	US	155,250	12.66	1 October- 1 November 2026	10,350	155,250	0.05%
23/26:6*	Employees	US	51,750	11.10	15 September - 1 November 2026	3,450	51,750	0.02%
SSP 24/27:1**	Employees	SE	621,600	2.90	1 October 2027- 1 November 2027	41,440	621,600	0.21%
SSP 24/27:2**	Board of Directors	SE	420,000	2.90	1 October 2027- 1 November 2027	28,000	420,000	0.14%
ESOP 24/27:3*	Employees	US	176,400	3.65	1 October 2027- 1 November 2027	11,760	176,400	0.06%
PRSU 24/27:4**	Employees	US	176,400	3.91	1 October 2027- 1 November 2027	11,760	176,400	0.06%
PRSU 2025/2028:1**	Board of Directors	SE	1,853,100	0.7416-1.0506	23 September 2028 - 23 October 2028	123,540	1,853,100	0.63%
PRSU 2025/2028:2**	Employees	SE	1,980,900	0.7416-1.0506	23 September 2028 - 23 October 2028	132,060	1,980,900	0.68%
PRSU 2025/2028:3**	Employees	US	1,022,400	0.7416-1.0506	23 September 2028 - 23 October 2028	68,160	1,022,400	0.35%
<b>7,306,800</b>						<b>487,120</b>	<b>7,306,800</b>	<b>2.50%</b>

Valuation is as per the Black & Scholes pricing model for Warrants/ Options\* and as per Monte Carlo simulation for Share Savings Program/Performance Share Program\*\*

## Incentive programs

The programs 23/26:3-6 were never implemented due to the unfavorable stock price trend during fall 2023.

Resolutions were passed at the EGM on 23 September 2025 on 3 performance share programs 25/28: 1–3, which were distributed during fall of 2025. The incentive programs distributed free-of-charge have been calculated and reported in accordance with IFRS 2. Accordingly, the increase in both personnel expenses (debit) and equity (credit), amounted to SEK 258 (238) in the fourth quarter. The corresponding figure for the entire fiscal year is SEK 819 (636) thousand. Additional information is available in the Annual Report for 2024/2025.

As of the closing date, the company had 7,306,800 (2,574,854) subscription rights, options and performance shares outstanding from the employee long-term incentive program. A total of 82,164 (52,830) of the stock options have been earned, a total of 5,644,908 (1,357,040) unearned but still possible to earn and the remainder expired since the person they had been allocated to had left the company.

## Shares

As of 30 April 2026, the number of outstanding shares in Biovica was 291,911,199, of which

14,423,973 shares are Class A and 277,487,226 shares are Class B. The total number of votes amounted to 320,759,145. The rights issue was implemented in July 2025 and the directed issue to anchor investors of the rights issue was implemented in August 2025. The proceeds from this were approximately SEK 122.3 million prior to issue costs and the set-off of a bridge loan.

## Subscription rights TO4 B

Based on the outcome of the rights issue that was published on 5 August 2025, the Board decided on 13 August 2025 to utilize the oversubscription option and carry out a directed share issue for a total of 67,002,517 Class B shares in the company to anchor investors, aimed at ensuring their full allocation in the rights issue.

As compensation to the anchor investors, they obtained, free-of-charge, the same number of Warrants from TO4 B (67,002,517) as the number of guaranteed shares, meaning that the company's share capital could increase by SEK 4,466,857 with full subscription of TO4 B.

One warrant of series TO4 B entitles the holder to subscription of one new Class B share in the company during the period ranging from registration of the warrants with the Swedish Companies Registration Office through 30 June 2030, at a subscription price of SEK 0.95 if the warrant is exercised by 30 June 2028, and at a

subscription price of SEK 1.25 if the warrant is exercised during the period from 1 July 2028 through 30 June 2030. For subscription of the Class B shares, the portion of the subscription price that exceeds the quotient value of the previous shares will be added to the share premium reserve. Full subscription at a price of SEK 0.95, would generate approximately SEK 63,652,391 for the company, prior to issue costs. Full subscription at a price of SEK 1.25, would generate approximately SEK 83,753,146 for the company, prior to issue costs. There was no subscription of TO4 B shares during the fiscal year.

### Reclassification of shares

At the end of each calendar quarter, class A shareholders are offered the opportunity of reclassifying their shares to B shares. Reclassification from Class A to Class B shares lowers the voting power, in that Class A shares carry three votes each and Class B shares carry one vote each. The Class A shares are unlisted, while Biovica's Class B shares are traded on Nasdaq First North Premier Growth Market, Stockholm. No reclassification occurred on 31 March 2026. A table showing share capital performance will be provided on page 31 of the printed version of the annual report, which will be published during the week of 29 June 2026.

### Policies for preparing the interim report

#### *Accounting policies*

This interim report was prepared in accordance with IAS 34, Interim Financial Reporting. The Group applies the Annual Accounts Act, International Financial Reporting Standards (IFRS) that have been adopted by the EU and RFR 1 Additional Accounting Regulations for Groups when preparing the financial statements. The Parent Company applies RFR 2 Accounting for Legal Entities when preparing the financial statements. The applied accounting policies correspond with those described in the Annual Report for 2024/2025.

#### *New standards and interpretations that enter into force in 2026 and later*

As of the date when these financial statements were approved for release, no new standards, revisions or interpretations of existing standards that have not yet entered into force or been published by IASB have been early-adopted by the Group.

### Significant risks and uncertainties

There are a number of risks and uncertainties associated with the company's operations, including market, regulatory and financial risks. For a more detailed description of the risks (in Swedish), please see the Annual Report for 2024/2025.

#### *Liquidity risk*

Conservatism in managing liquidity risk involves holding sufficient liquid funds or agreed credit facilities in order to be able to run the business.

The Board of Directors has performed a comprehensive assessment of the company's financing needs and liquidity position. The assessment is based on the company's cash and cash equivalents of approximately SEK 70 million at the end of the period, as well as a forecast approved by the Board of Directors regarding sales development and cost structure. Based on this analysis, the Board of Directors assesses that the company has sufficient resources to continue its operations for the foreseeable future which means minimum next 12 months after this report has been published.

The Board of Directors' assessment is based on assumptions regarding future sales development and costs. If actual outcomes differ materially from the assumptions underlying the forecast, this could affect the company's liquidity and, consequently, its ability to continue as a going concern. Accordingly, the Board of Directors has not identified any material uncertainties that could raise significant doubt about the company's ability to continue as a going concern, based on currently known circumstances. Accordingly, the Board of Directors considers the use of the going concern basis of accounting to be appropriate in the preparation of the financial statements.

#### *Uncertainties in the global situation*

The Board and management continuously monitor the global situation and the increased risks arising from, among other things, Russia's invasion of Ukraine and the war in the Middle East. An increased risk of trade wars and the introduction of high tariffs – particularly between Europe and the United States – could negatively impact the company's earning capacity.

#### *Financial risk management*

The Group's business activities are associated with a variety of financial risks such as currency risk and interest rate risk on cash flows, credit risk and

liquidity risk. The Group's overall risk management policy, which has been established by the Board, is to strive for minimal adverse effects on financial results and financial position.

#### ***Currency risks***

The Group has operations both domestically (in Sweden) and internationally, which means that there is exposure to fluctuations in different currencies, particularly USD and EUR. Currency risk arises through future business transactions and reported assets and liabilities. The increased scope of the company's operations has increased its net exposure to foreign currencies compared to prior years.

#### ***Interest rate risk on cash flows***

Interest rate risk is the risk that the value of financial instruments will fluctuate due to changes in market interest rates. The Group currently only has interest-bearing financial assets in the form of bank balances, which is why this risk is assessed as low.

#### ***Credit risk***

Credit risk is the risk that a party to a transaction involving a financial instrument is unable to fulfill its obligation. Exposure to credit risks is marginal for both the Group and Parent Company.

### Significant assessments

#### ***Assessments and estimates in the financial statements***

In preparing the financial statements, the executive management team must make assessments and estimates that affect both the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. The actual outcome may deviate from these estimates and assessments. A selection of these assessments is presented below.

#### ***Revenue from contracts with customers***

Revenue from contracts with customers is reported at net realizable value and recognized when the performance obligation has been fulfilled and control over the goods or services has been transferred to the customer, in accordance with IFRS 15. This assessment shall occur from the customer's perspective, taking into consideration such things as transfer of ownership and risks, the customer's acceptance, physical access and the right to invoice. An assessment must also be made of whether control has been transferred at a specific point in time, or over time. All net sales represent point-in-time revenue and are recognized

at the amount expected to be received. No sales are reported as sales over time. The timing of revenue recognition for services coincides with the reporting of test results to the customer. For goods, revenue is recognized when the risks and rewards associated with the item are transferred to the customer. Revenue is recognized at net realizable value at a specific point in time, which is when control of the goods or services has been transferred to the customer. The contract terms and conditions may vary but typically, transfer of control and thus revenue recognition occurs at the time of delivery.

#### ***Segment reporting***

The Group's operations consist of development, manufacturing and sales of blood analysis products. The Group's organizational structure is by function as follows: production, sales & marketing, administration and R&D. The Group is considered to be a single unit, where all of its sub-components are integrated and dependent upon each other. Biovica's highest decision-making body monitors the consolidated income statement and statement of comprehensive income.

#### ***Intangible assets***

Expenditure for research that is for the purpose of gaining new scientific or technical knowledge is expensed as incurred. Expenditure for development (where the research results or other knowledge is used to achieve new or improved products or processes) is recognized as an intangible fixed asset in the statement of financial position if the product or process is technically or commercially usable and the company has adequate resources for monitoring the development and thereafter using or selling the intangible asset. Decisions on whether or not to capitalize expenditure on development projects are made by the company's Board of Directors based on documentation and support provided by the Audit Committee. The decision is based on whether it is possible to implement the project using existing or future resources and on whether conclusion of the project and launch is expected to occur in the foreseeable future. Directly attributable expenditure that is capitalized as part of the cost of the asset includes expenditure for employees and materials. With capitalization, consideration is given to the portion of expenditure recognized as revenue against received/expected grants. Capitalized development expenditure is reported as intangible assets and amortized as of the date when the asset is ready for use. The estimated useful life for capitalized development

expenditures is 10 years. Other development expenses are recognized in the income statement as incurred. Patents are recognized at the cost of acquisition and they are amortized on a straight-line basis over their estimated useful lives. The estimated useful life is assessed based on the legal life of the patent.

For a detailed description of these assessments, please see the Annual Report for 2024/2025.

### Note 1. Sales per product group

Net sales for the fourth quarter are derived from the following product groups:

	Q4		%
	2025/2026	2024/2025	
Tests (IVD) – USA	1,100	934	18%
Kits (IVD) – EU	-	-	-
Pharma Services: Tests (RUO)	2,813	329	755%
Pharma Services: Kits (RUO)	902	1,069	-16%
<b>Total net sales</b>	<b>4,815</b>	<b>2,332</b>	<b>106%</b>

Corresponding figures for the fiscal year

	May-April		%
	2025/2026	2024/2025	
Tests (IVD) – USA	4,087	2,953	38%
Kits (IVD) – EU	-	264	-
Pharma Services: Tests (RUO)	6,927	2,280	204%
Pharma Services: Kits (RUO)	2,366	3,123	-24%
<b>Total net sales</b>	<b>13,380</b>	<b>8,619</b>	<b>55%</b>

### Note 2 Reclassification of materials costs and inventory changes

As of Q2 of the 2025/2026 fiscal year, the Group has changed the presentation of certain production-related costs in the income statement. Direct labor costs and manufacturing overhead allocations incurred in production are no longer

recognized as Materials cost and are instead included in Changes in inventory.

The reclassification was made to better reflect the link between production costs and changes in inventory, resulting in a more accurate presentation of the cost structure.

The change affects neither operating income nor net income for the year and relates solely to a reclassification between line items in the income statement.

Comparative figures have not been restated, as the change relates solely to classification and has no impact on earnings.

### Note 3 Earnings per Share

Earnings per share are calculated in accordance with IAS 33 as the profit for the period attributable to the shareholders of the parent company divided by the weighted average number of shares outstanding during the period.

During the financial year, the company carried out a rights issue in which existing shareholders were offered to subscribe for new shares at a subscription price below the market price of the share prior to the detachment of subscription rights. Such issues are, in accordance with IAS 33, considered to contain a bonus element and shall be taken into account in the calculation of earnings per share by adjusting comparative figures.

The adjustment factor has been calculated as the ratio between the share price before the detachment of subscription rights and the theoretical share price after the issue (TERP). The calculated adjustment factor amounts to approximately 1.03.

After adjustment, earnings per share for the financial year amount to approximately SEK 0.29, compared with the reported figure of SEK 0.30. The effect of approximately SEK 0.01 per share (approximately 3 percent) is not considered to have a material impact on the overall analysis of the company's earnings per share.

## KPIs for the Group

SEK 000s	Q4 25/26	Q4 24/25	Full year 25/26	Full year 24/25
Net sales	4,815	2,332	13,380	8,619
Operating profit (loss)	-18,043	-20,341	-70,119	-85,839
Profit (loss) for the period	-19,122	-20,766	-69,860	-87,624
Capitalized R&D costs	0	0	0	0
Capitalized R&D exp., % of op. expenses	0	0	0	0
Earnings per share, before dilution, SEK (note 3)	-0.07	-0.21	-0.30	-0.95
Earnings per share, after dilution, SEK (note 3)	-0.07	-0.21	-0.30	-0.95
Cash and cash equivalents at the end of the period	70,412	24,415	70,412	24,415
Cash flow from operating activities	-15,984	-17,826	-62,807	-85,367
Cash flow for the period	-17,896	-18,748	46,076	-54,730
Equity	86,333	43,206	86,333	43,206
Equity per share, SEK	0.30	0.44	0.30	0.44
Equity ratio (%)	80%	67%	80%	67%
Average number of employees	25	26	24	26

Definitions are the same as those presented in the Annual Report for 2024/2025.

### Alternative key performance indicators

Of the KPIs presented above, the only one that is obligatory to report, and which is defined in accordance with IFRS is: Earnings per share, before and after dilution. For the other KPIs, the following are in accordance with IFRS presentation requirements: Profit (loss) for the year, Cash & cash equivalents at the end of the period, Cash flow for the period and Equity.

KPIs	Definition	Reason for using alternative KPIs, which are not defined in accordance with IFRS.
Net sales	Income from goods sold	Shows the demand for the product.
Operating profit (loss)	Profit (loss) before financial items and tax.	Operating profit (loss) is an indication of the company's earnings generated from ordinary operations.
Earnings per share, before and after dilution	Profit (loss) divided by the weighted average number of shares during the period, before and after dilution.	
Cash & cash equivalents and short-term investments	Bank balances and short-term investments	
Cash flow from operating activities	Cash flow before the cash flow from investing activities and financing activities	
Cash flow for the period	Change in cash & cash equivalents for the period not including the effect from unrealized exchange gains and losses.	
Equity per share	Equity divided by the number of shares at the end of the period.	Management uses this KPI to monitor the value of equity per share.
Equity ratio	Equity as a percentage of total assets.	Management uses this KPI because it provides an indication of the company's financial stability.
Average number of employees	The average number of employees is calculated as the average during the period of the number of employees per month.	

## Consolidated income statement and summary statement of comprehensive income

	Q4 2025/2026	Q4 2024/2025	May-April 2025/2026	May-April 2024/2025
<b>Amount in SEK thousands</b>				
Net sales	4,815	2,332	13,380	8,619
Other income	207	932	627	2,341
<b>Operating income</b>	<b>5,022</b>	<b>3,264</b>	<b>14,006</b>	<b>10,961</b>
Change in WIP inventory	195	0	1,091	0
Materials cost	-450	125	-1,134	-535
Other external costs	-7,044	-7,141	-25,756	-28,332
Employee benefit expenses	-13,612	-13,630	-49,333	-57,299
Depreciation/amortization	-1,998	-2,160	-8,295	-8,843
Other operating expenses	-155	-798	-699	-1,791
<b>Operating expenses</b>	<b>-23,065</b>	<b>-23,604</b>	<b>-84,126</b>	<b>-96,800</b>
<b>Operating profit (loss)</b>	<b>-18,043</b>	<b>-20,341</b>	<b>-70,119</b>	<b>-85,839</b>
Financial income	383	346	1,007	996
Financial expenses	-37	-246	-396	-1,139
<b>Profit (loss) before tax</b>	<b>-17,697</b>	<b>-20,240</b>	<b>-69,508</b>	<b>-85,982</b>
Tax	-1,425	-526	-352	-1,641
<b>Profit (loss) for the period</b>	<b>-19,122</b>	<b>-20,766</b>	<b>-69,860</b>	<b>-87,624</b>
<b>Consolidated statement of comprehensive income</b>				
Profit (loss) for the period	-19,122	-20,766	-69,860	-87,624
Exchange differences when translating foreign operations	243	-632	-170	-632
Other comprehensive income for the period	0	0	0	0
<b>Comprehensive income for the period</b>	<b>-18,879</b>	<b>-21,398</b>	<b>-70,031</b>	<b>-88,256</b>
<b>Earnings per share</b>				
Earnings per share, before dilution SEK (note 3)	-0.07	-0.21	-0.30	-0.95
Average number of shares, before dilution	291,911,199	97,786,384	234,796,495	92,569,248
Earnings per share, after dilution SEK (note 3)	-0.07	-0.21	-0.30	-0.95
Average number of shares, after dilution	291,911,199	97,786,384	234,796,495	92,569,248

## Consolidated statement of financial position, in summary

Amount in SEK thousands	2026-04-30	2025-04-30
<b>ASSETS</b>		
Intangible assets	21,720	26,536
Machinery, equipment, tools, fixtures and fittings	1,151	1,049
Right-of-use assets	3,268	3,719
Other non-current receivables	382	396
Deferred tax asset	885	2,455
<b>Total fixed assets</b>	<b>27,406</b>	<b>34,154</b>
Inventories	2,290	1,930
Accounts receivable	4,721	1,815
Current receivables	2,921	2,634
Cash and cash equivalents	70,412	24,415
<b>Total current assets</b>	<b>80,344</b>	<b>30,794</b>
<b>TOTAL ASSETS</b>	<b>107,749</b>	<b>64,949</b>
<b>EQUITY</b>		
Share capital	19,461	6,519
Other contributed capital	678,040	577,824
Reserves	-393	-222
Retained earnings (losses), including loss for the period	-610,775	-540,915
<b>Total equity</b>	<b>86,333</b>	<b>43,206</b>
<b>LIABILITIES</b>		
Right-of-use liabilities	1,752	1,736
Deferred tax liability	963	1,849
<b>Total non-current liabilities</b>	<b>2,716</b>	<b>3,585</b>
Right-of-use liabilities	2,546	2,915
Advance payments from customers	1,732	0
Accounts payable	3,127	3,544
Current tax liabilities	51	14
Other liabilities	863	912
Accrued expenses and deferred income	10,382	10,774
<b>Current liabilities</b>	<b>18,701</b>	<b>18,158</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>107,749</b>	<b>64,949</b>

## Consolidated statement of changes in equity, in summary

Amount in SEK thousands	Share capital	Other contributed capital	Reserves	Retained earnings	Total equity
<b>Opening balance, 1 May 2024</b>	<b>5,604</b>	<b>543,918</b>	<b>410</b>	<b>-453,291</b>	<b>96,640</b>
Appropriation in accordance with AGM decision					0
New share issue	915	34,922			35,837
Issue fees		-1,604			-1,604
Share-based payments, employees		588			588
<b>Transaction with owners</b>	<b>6,519</b>	<b>577,824</b>	<b>410</b>	<b>-453,291</b>	<b>131,461</b>
Profit (loss) for the year				-87,624	-87,624
Other comprehensive income			-632		-632
<b>Comprehensive income for the year (loss)</b>	<b>0</b>	<b>0</b>	<b>-632</b>	<b>-87,624</b>	<b>-88,257</b>
<b>Closing balance, 30 April 2025</b>	<b>6,519</b>	<b>577,824</b>	<b>-222</b>	<b>-540,915</b>	<b>43,206</b>
<b>Opening balance, 1 May 2025</b>	<b>6,519</b>	<b>577,824</b>	<b>-222</b>	<b>-540,915</b>	<b>43,206</b>
Appropriation in accordance with AGM decision					0
New share issue	12,942	109,357			122,299
Issue fees		-9,947			-9,947
Share-based payments, employees		805			805
<b>Transaction with owners</b>	<b>19,461</b>	<b>678,040</b>	<b>-222</b>	<b>-540,915</b>	<b>156,363</b>
Profit (loss) for the year				-69,860	-69,860
Other comprehensive income			-170		-170
<b>Comprehensive income for the year (loss)</b>	<b>0</b>	<b>0</b>	<b>-170</b>	<b>-69,860</b>	<b>-70,031</b>
<b>Closing balance, 30 April 2026</b>	<b>19,461</b>	<b>678,040</b>	<b>-393</b>	<b>-610,775</b>	<b>86,332</b>

## Consolidated statement of cash flows, in summary

Amount in SEK thousands	Q4 25/26	Q4 24/25	May-April 25/26	May-April 24/25
<b>Cash flow from operating activities before changes in working capital</b>	<b>-15,151</b>	<b>-18,045</b>	<b>-60,021</b>	<b>-77,113</b>
Change in current receivables	-1,597	-1,183	-3,445	-216
Change in current liabilities	891	2,051	1,086	-7,953
Change in inventories	-126	-649	-426	-85
<b>Changes in working capital</b>	<b>-832</b>	<b>219</b>	<b>-2,786</b>	<b>-8,254</b>
<b>Cash flow from operating activities</b>	<b>-15,984</b>	<b>-17,826</b>	<b>-62,807</b>	<b>-85,367</b>
<i>Investing activities</i>				
Investments in PPE	-288	-78	-474	-287
<b>Cash flow from investing activities</b>	<b>-288</b>	<b>-78</b>	<b>-474</b>	<b>-287</b>
<i>Financing activities</i>				
New share issue	0	0	122,299	35,837
Issue fees	-1,021	0	-9,947	-1,604
Borrowings	0	0	10,000	0
Amortization of loans	-603	-844	-12,996	-3,309
<b>Cash flow from financing activities</b>	<b>-1,624</b>	<b>-844</b>	<b>109,356</b>	<b>30,925</b>
<b>Cash flow for the period</b>	<b>-17,896</b>	<b>-18,748</b>	<b>46,076</b>	<b>-54,730</b>
Cash and cash equivalents at the beginning of the period	88,223	43,508	24,415	79,407
Translation difference, cash and cash equivalents	85	-345	-79	-262
Cash and cash equivalents at the end of the period	70,412	24,415	70,412	24,415

## Parent Company income statement, in summary

Amount in SEK thousands	Q4 2025/2026	Q4 2024/2025	May-April 2025/2026	May-April 2024/2025
Net sales	3,713	5,272	10,094	28,385
Other operating income	207	932	627	2,341
<b>Total revenue</b>	<b>3,920</b>	<b>6,204</b>	<b>10,721</b>	<b>30,726</b>
Change in WIP inventory	404	0	953	0
Materials cost	-346	198	-1,673	-640
Other external costs	-12,308	-18,970	-48,493	-78,062
Employee benefit expenses	-8,125	-7,521	-29,322	-33,024
Depreciation/amortization	-1,262	-1,242	-4,994	-5,217
Other expenses	-155	-798	-699	-1,791
<b>Operating expenses</b>	<b>-21,792</b>	<b>-28,334</b>	<b>-84,228</b>	<b>-118,734</b>
<b>Operating profit (loss)</b>	<b>-17,872</b>	<b>-22,130</b>	<b>-73,507</b>	<b>-88,008</b>
Financial income	111	0	1,119	994
Financial expenses	0	-550	-234	-975
<b>Profit (loss) before tax</b>	<b>-17,761</b>	<b>-22,680</b>	<b>-72,621</b>	<b>-87,990</b>
Tax on profit for the period	0	0	0	0
<b>Profit (loss) for the period</b>	<b>-17,761</b>	<b>-22,680</b>	<b>-72,621</b>	<b>-87,990</b>

Comprehensive income (loss) equals the loss for the period.

## Parent Company balance sheet, in summary

Amount in SEK thousands	2026-04-30	2025-04-30
<b>ASSETS</b>		
Intangible assets	21,720	26,536
Machinery, equipment, tools, fixtures and fittings	878	636
Financial assets	827	4,082
<b>Total fixed assets</b>	<b>23,424</b>	<b>31,254</b>
Inventories	2,088	1,866
Current receivables	4,919	2,915
Cash and cash equivalents	68,183	22,722
<b>Total current assets</b>	<b>75,190</b>	<b>27,504</b>
<b>TOTAL ASSETS</b>	<b>98,615</b>	<b>58,758</b>
<b>EQUITY</b>		
Restricted equity	37,172	27,567
Non-restricted equity	44,422	13,491
<b>Total EQUITY</b>	<b>81,595</b>	<b>41,059</b>
<b>LIABILITIES</b>		
Current liabilities	17,020	17,699
<b>Total LIABILITIES</b>	<b>17,020</b>	<b>17,699</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>98,615</b>	<b>58,758</b>

## Glossary

**Abstract** A short summary of a longer document, such as a dissertation or research article. It briefly states the purposes and results of the research. Abstracts are submitted to scientific conferences in order to spread knowledge of new research.

**Imaging** These are methods that currently serve as the cornerstones for diagnostics and treatment planning for essentially all types of solid tumors. It includes computer tomography (CT) scans and other X-ray methods, magnetic resonance tomography (MRT) scans, positron emission tomography (PET) scans and ultrasound.

**CDK4/6 inhibitors** A new type of targeted, selective drugs that have been shown to be effective against several forms of cancers, including hormone receptor-positive breast cancer.

**CLIA laboratory** (The Clinical Laboratory Improvement Amendments): a clinical laboratory that has been certified to accept human samples from people in the USA for diagnostic testing. The Center for Medicare and Medicaid Services (CMS) is the regulatory body that grants certification.

**Companion Diagnostics** Also called CDx. These are diagnostic tests used to identify patients that would likely respond to a specific treatment, as well as to monitor the treatment effect on individual patients. They thus facilitate personalization of treatment.

**Fulvestrant (Faslodex)** A drug that is used to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression and HR-positive, HER2-negative advanced breast cancer in combination with palbociclib in women with disease progression after endocrine treatment. Fulvestrant is a Selective Estrogen Receptor Degradar (SERD).

**IVD** In vitro diagnostics (IVD) are generally defined as a product which, regardless of whether they are used alone or in combination, are designed for performing in vitro tests on samples that have been taken from the human body. The main purpose is to obtain information for diagnostic, monitoring or compatibility purposes.

**KOL** Key Opinion Leaders. Trusted, well-respected influencers with proven experience in a particular field.

**Palbociclib** A new type of targeted, selective drug that has been shown to be effective against several

forms of cancers, including hormone receptor-positive breast cancer.

**Posters** These are used to summarize information or research and present it in an attractive way as a means of generating interest in publishing it and sparking discussion at events such as scientific conferences.

**Predictive** Anticipation about what will happen in the future and used in the contexts like the predictive ability of a particular test.

**PREDIX study** A randomized trial of neoadjuvant chemotherapy to treat HER2-positive breast cancer that was carried out during the period 2014–2019 at nine Swedish clinics under the supervision of Karolinska Institutet (KI).

**Prospective studies** Used to study the relationship between various risk factors and a particular disease. This type of study follows individuals both with risk factors and without (the control group), for a period of time into the future. At the end of the study, a comparison is made of the percentage that fell ill in each group.

**PYTHIA study** A clinical study of patients with metastatic breast cancer. The primary aim of the PYTHIA study is to discover potentially innovative biomarkers for the selection of patients to Palbociclib/Fulvestrant treatment.

**Reimbursement** Compensation for costs (in this context, it is payment from insurance companies to cover treatment costs)

**RUO Research Use Only** An ROU product is an IVD (In Vitro Diagnostic) product that is in the development stage and may only be used for laboratory research and clinical studies.

**SABCS** San Antonio Breast Cancer Symposium is an international scientific symposium on breast cancer held each year in December in San Antonio Texas, USA.

**Thymidine kinase** is an enzyme (kinase), subclass of phosphotransferase.

**Estrogen receptor-positive** To determine whether a patient might benefit from hormone treatment, the tumor is studied to assess whether receptors for either estrogen or progesterone. If so, it is hormone-receptor positive, which is the case for around 70 percent of all breast cancer tumors. It is

primarily estrogen that has a stimulating effect on tumor growth.

This report has not been reviewed by the company's auditor.

### ***The Board of Directors' and CEO's assurance***

*The Board of Directors and CEO hereby certify that this interim report provides a true and fair summary of the Parent Company's and the Group's operations, earnings and financial position as well as describing any significant risks or uncertainties faced by the Parent Company or any of the companies belonging to the Group.*

Uppsala, 30 June 2026

Fredrik Alpsten  
*Chairman of the Board*

Cornelis Peter (Niels) Bogerd  
*Board member*

Annika Carlsson Berg  
*Board member*

Marie-Louise Fjällskog  
*Board member*

Maria Holmlund  
*Board member*

Jesper Söderqvist  
*Board member*

Anders Rylander  
*Board member*

Theis Kipling  
*CEO*

### Calendar

Annual Report	week of 29 June–3 July 2026
Interim Report for Q1: May–July 2026/2027	10 September 2026
AGM 2026	16 Sept 2026
Interim Report Q2: August–October 2026/2027	17 December 2026
Interim Report Q3: November–January 2026/2027	11 March 2027
Year-end report: February–April 2026/2027	17 June 2027

For more information, please contact:

Theis Kipling, CEO  
Phone: +46 (0)18-44 44 835  
E-mail: [theis.kipling@biovica.com](mailto:theis.kipling@biovica.com)

Anders Morén, CFO  
Phone +46 (0)73 125 92 46  
E-mail: [anders.moren@biovica.com](mailto:anders.moren@biovica.com)

Biovica International AB (publ), 556774-6150  
Dag Hammarskjölds väg 54B  
752 37 Uppsala  
+46 (0)18-44 44 830

### **Biovica – Treatment decisions with greater certainty**

Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum Tka, measures cell proliferation by detecting the Tka biomarker in the bloodstream. The first application for DiviTum Tka is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum Tka has obtained FDA 510(k) clearance in the USA and has CE marking in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information,

Biovica International AB (publ)

Year-end report Q4 2025/2026

This is a translation of the Swedish original Year-End Report. In the event of any discrepancies, the Swedish version shall prevail

please visit: [www.biovica.com](http://www.biovica.com)